822P Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM).

Autor:	Abdel-Wahab, N.1 (AUTHOR), Montazari, E.J.2 (AUTHOR), Spillson, C.2 (AUTHOR), Amaria, R.2 (AUTHOR), Glitza, I.C.2 (AUTHOR), Patel, S.2 (AUTHOR), Awiwi, M.3 (AUTHOR), Hassan, A.3 (AUTHOR), Tahon, N.3 (AUTHOR), Elsayes, K.M.3 (AUTHOR), Altan, M.4 (AUTHOR), Wong, M.2 (AUTHOR), Mcquade, J.2 (AUTHOR), Tawbi, H.A.2 (AUTHOR), Davies, M.2 (AUTHOR), Yee, C.2 (AUTHOR), Sharma, P.5 (AUTHOR), Allison, J.6 (AUTHOR), Johnson, D.7 (AUTHOR), Diab, A.2 (AUTHOR)
Zdroj:	Annals of Oncology. 2022 Supplement 7, Vol. 33, pS923-S923. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu